Research progress of gammadelta T cell-based immunotherapy.
- Author:
Fu-ming QIU
1
;
Zhong-peng LI
;
Jian HUANG
Author Information
1. Department of Oncology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Immunotherapy;
methods;
Immunotherapy, Adoptive;
methods;
Neoplasms;
immunology;
therapy;
Receptors, Antigen, T-Cell, gamma-delta;
immunology;
T-Lymphocyte Subsets;
immunology
- From:
Journal of Zhejiang University. Medical sciences
2010;39(4):424-429
- CountryChina
- Language:Chinese
-
Abstract:
GammadeltaT cells are considered as linkage between innate and adaptive immune response, which recognize specific antigen without MHC-restriction. Vgamma9Vdelta2T cells, isolated from peripheral blood and tumor tissue, can be activated by non-peptide phosphoantigen through binding to its gammadeltaTCR and proliferate under IL-2 stimulation. It has been shown that Vgamma9Vdelta2T cells possess anticancer activity against several types of tumor in vitro, as well as inhibit the growth of lymphoma, breast cancer and malignant melanoma in vivo. The phase I clinical trial of the application of Vgamma9Vdelta2T cells in treatment of lung cancer, renal cancer and prostate cancer demonstrated promising results. This review summarizes the recent advances in antigen recognition and activation of gammadeltaT cells, and the gammadeltaT cell-based immunotherapy for cancer treatment.
